Novartis signs $50-m deal with Mesoblast for Covid, respiratory diseases treatment
It has the potential to be the first treatment for the most critically ill ARDS patients'20-11-2020
20-11-2020
NOVARTIS INDIA LTD. - 500672 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Please note that in terms of the applicable provisions of the SEBI Listing Regulations, the Company has received intimation regarding loss of share certificate from the following shareholder: Stop transfer date - November 12, 2020 Folio no. 02072441 Name - Deepak Dhirajlal Dave Certificate no. 11573 Distinctive no. 3915037 -3915066 No. of shares - 30 Reason - lost by holder The Registrar and Share Transfer Agent of the Company i.e. Link lntime India Private Limited has received a request letter from the above mentioned shareholder and accordingly have informed the Company which was noted on November 17, 2020 (due to festive holidays of the Company). Further, subject to completion of required formalities by the shareholder, the Company will issue duplicate share certificate in lieu thereof. Thanking you..18-11-2020
Novartis announces BioCamp for young researchers in India
The next edition of the conclave takes place virtually, in January 202107-11-2020
NOVARTIS INDIA LTD. - 500672 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Intimation of Newspaper advertisement by Novartis India Limited regarding the Unaudited Financial Results of the Company for the second quarter and half year ended September 30, 2020 in 'Financial Express' and 'Navshakti' on November 6, 2020. This is for your information and record.06-11-2020
Novartis India Q2 net profit at Rs 7.52 crore
The company had posted a net loss of Rs 5.22 crore for the corresponding period previous fiscal, Novartis India said in a BSE filing.05-11-2020
NOVARTIS INDIA LTD. - 500672 - Appointment Of Ms. Bhavna Gupta As The Internal Auditor Of The Company W.E.F. November 5, 2020,
Pursuant to the recommendation of the Nomination and Remuneration Committee and Audit Committee, Board of Directors of the Company at its meeting held today i.e. November 5, 2020, approved the appointment of Ms. Bhavna Gupta as the Internal Auditor of the Company w.e.f. November 5, 2020, brief profile of Ms. Gupta is enclosed as Annexure 2.05-11-2020
NOVARTIS INDIA LTD. - 500672 - Unaudited Financial Results Of The Company For The Quarter And Half Year Ended On September 30, 2020.
Kindly note that the Board of Directors of the Company has in its meeting held today i.e. on Thursday, November 5, 2020 ("said meeting"), inter alia considered and approved the Unaudited Financial Results of the Company for the quarter and half year ended on September 30, 2020. In terms of the applicable provisions of SEBI Listing Regulations, please find enclosed herewith: a. the Unaudited Financial Results; and b. Limited Review Report dated November 5, 2020, issued by the Statutory Auditors of the Company with respect to the Unaudited Financial Results and taken on record by the Board of Directors of the Company, as Annexure 1.05-11-2020
NOVARTIS INDIA LTD. - 500672 - Outcome Of The Meeting Of The Board Of Directors Of Novartis India Limited ('The Company') Held On November 5, 2020
Kindly note that the Board of Directors of the Company has in its meeting held today i.e. on Thursday, November 5, 2020 ("said meeting"), inter alia considered and approved the Unaudited Financial Results of the Company for the quarter and half year ended on September 30, 2020. Further, pursuant to the recommendation of the Nomination and Remuneration Committee and Audit Committee, Board of Directors of the Company at its meeting held today approved the appointment of Ms. Bhavna Gupta as the Internal Auditor of the Company w.e.f. November 5, 2020, brief profile of Ms. Gupta is enclosed as Annexure 2. The said Meeting commenced at 11:45 a.m. and concluded at 2:00 p.m. The above is for your information and the same is also available on the Company''s website i.e. www.novartis.in05-11-2020
NOVARTIS INDIA LTD. - 500672 - Compliance Certificate Obtained By Novartis India Limited ('The Company') From A Practising Company Secretary For The Half Year Ended On September 30, 2020, In Terms Of The Provisions Of Regulations 40(9) & (10) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations")
Please note that in terms of the SEBI Listing Regulations, the Company has obtained a Compliance Certificate from Saraf & Associates, Company Secretaries, for the half year ended on September 30, 2020 and the same is being submitted herewith. This is for your information and record.28-10-2020
Novartis, Molecular Partner team up on coronavirus candidates treatment
Novartis has licenced global rights to two Molecular Partners antiviral drugs that have potential to treat Covid-19 patients, the two companies said28-10-2020